Article
ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.
Cancer research - 1 Dec 2014
Goetz Eva M, Ghandi Mahmoud, Treacy Daniel J, Wagle Nikhil, Garraway Levi A
Abstract excerpt
The use of targeted therapeutics directed against BRAF(V600)-mutant metastatic melanoma improves progression-free survival in many patients; however, acquired drug resistance remains a major medical challenge. By far, the most common clinical resistance mechanism involves reactivation of the MAPK (RAF/MEK/ERK) pathway by a variety of mechanisms. Thus, targeting ERK itself has emerged as an attractive therapeutic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.